1047634-63-8

Basic information

• Product Name: GSK2110183
• Synonyms: GSK2110183;Afuresertib (GSK2110183);N-[(1S)-2-Amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide
• CAS NO: 1047634-63-8
• Molecular Formula: C18H16Cl2F2N4OS
• Molecular Weight: 445.3136464
• Mol File: 1047634-63-8.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: GSK2110183(CAS DataBase Reference)
• NIST Chemistry Reference: GSK2110183(1047634-63-8)
• EPA Substance Registry System: GSK2110183(1047634-63-8)

Safety Data

• Hazardous Substances Data: 1047634-63-8(Hazardous Substances Data)

Usage

Description

GSK2110183 is a potent and selective inhibitor of 5-lipoxygenase-activating protein (FLAP), an enzyme involved in the biosynthesis of leukotrienes, which are inflammatory mediators implicated in asthma and other inflammatory diseases. By inhibiting FLAP, GSK2110183 effectively blocks leukotriene synthesis, reducing inflammation and alleviating related symptoms. GSK2110183 has demonstrated potential as a treatment for asthma and other inflammatory conditions, showing promise in preclinical studies. Its inhibitory activity on FLAP also makes it a valuable tool for investigating the role of leukotrienes in disease pathology and for developing novel therapeutic strategies targeting this pathway.

Uses

Used in Pharmaceutical Industry:
GSK2110183 is used as an anti-inflammatory agent for its ability to inhibit the synthesis of leukotrienes, which are key mediators in inflammatory processes. This makes it a potential treatment for asthma and other inflammatory conditions, where reducing leukotriene levels can help alleviate symptoms and improve patient outcomes.
Used in Research and Development:
GSK2110183 is used as a research tool for studying the role of leukotrienes in disease pathology. Its inhibitory activity on FLAP allows scientists to better understand the mechanisms by which leukotrienes contribute to inflammation and to explore the potential of targeting this pathway for therapeutic intervention.
Used in Drug Discovery:
GSK2110183 serves as a lead compound in the development of new therapies targeting the FLAP enzyme. Its selectivity and potency make it a promising starting point for the design of more effective and safer drugs to treat asthma and other inflammatory diseases.